Grant McArthur
Grant McArthur
Peter MacCallum Cancer Centre
Verified email at petermac.org
Title
Cited by
Cited by
Year
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
PB Chapman, A Hauschild, C Robert, JB Haanen, P Ascierto, J Larkin, ...
New England Journal of Medicine 364 (26), 2507-2516, 2011
77372011
Combined nivolumab and ipilimumab or monotherapy in untreated melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, CL Cowey, CD Lao, ...
New England journal of medicine 373 (1), 23-34, 2015
56112015
Inhibition of mutated, activated BRAF in metastatic melanoma
KT Flaherty, I Puzanov, KB Kim, A Ribas, GA McArthur, JA Sosman, ...
New England Journal of Medicine 363 (9), 809-819, 2010
37912010
Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial
GD Demetri, AT van Oosterom, CR Garrett, ME Blackstein, MH Shah, ...
The Lancet 368 (9544), 1329-1338, 2006
27522006
Survival in BRAF V600–mutant advanced melanoma treated with vemurafenib
JA Sosman, KB Kim, L Schuchter, R Gonzalez, AC Pavlick, JS Weber, ...
New England Journal of Medicine 366 (8), 707-714, 2012
22202012
Melanomas acquire resistance to B-RAF (V600E) inhibition by RTK or N-RAS upregulation
R Nazarian, H Shi, Q Wang, X Kong, RC Koya, H Lee, Z Chen, MK Lee, ...
Nature 468 (7326), 973-977, 2010
22082010
Overall survival with combined nivolumab and ipilimumab in advanced melanoma
JD Wolchok, V Chiarion-Sileni, R Gonzalez, P Rutkowski, JJ Grob, ...
New England Journal of Medicine 377 (14), 1345-1356, 2017
21462017
Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
J Larkin, PA Ascierto, B Dréno, V Atkinson, G Liszkay, M Maio, M Mandalà, ...
New England Journal of Medicine 371 (20), 1867-1876, 2014
17862014
Clinical efficacy of a RAF inhibitor needs broad target blockade in BRAF-mutant melanoma
G Bollag, P Hirth, J Tsai, J Zhang, PN Ibrahim, H Cho, W Spevak, C Zhang, ...
Nature 467 (7315), 596-599, 2010
17062010
Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K
J Villanueva, A Vultur, JT Lee, R Somasundaram, M Fukunaga-Kalabis, ...
Cancer cell 18 (6), 683-695, 2010
12962010
Melanoma staging: evidence‐based changes in the American Joint Committee on Cancer eighth edition cancer staging manual
JE Gershenwald, RA Scolyer, KR Hess, VK Sondak, GV Long, MI Ross, ...
CA: a cancer journal for clinicians 67 (6), 472-492, 2017
11372017
RAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
F Su, A Viros, C Milagre, K Trunzer, G Bollag, O Spleiss, JS Reis-Filho, ...
New England Journal of Medicine 366 (3), 207-215, 2012
10282012
Oncogenic signaling pathways in the cancer genome atlas
F Sanchez-Vega, M Mina, J Armenia, WK Chatila, A Luna, KC La, ...
Cell 173 (2), 321-337. e10, 2018
9952018
Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study
GA McArthur, PB Chapman, C Robert, J Larkin, JB Haanen, R Dummer, ...
The lancet oncology 15 (3), 323-332, 2014
9822014
Five-year survival with combined nivolumab and ipilimumab in advanced melanoma
J Larkin, V Chiarion-Sileni, R Gonzalez, JJ Grob, P Rutkowski, CD Lao, ...
New England Journal of Medicine 381 (16), 1535-1546, 2019
9432019
Prognostic significance of p16INK4A and human papillomavirus in patients with oropharyngeal cancer treated on TROG 02.02 phase III trial
D Rischin, RJ Young, R Fisher, SB Fox, QT Le, LJ Peters, B Solomon, ...
Journal of clinical oncology 28 (27), 4142, 2010
7552010
Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma
A Ribas, R Kefford, MA Marshall, CJA Punt, JB Haanen, M Marmol, ...
Journal of clinical oncology 31 (5), 616, 2013
7332013
Cobimetinib combined with vemurafenib in advanced BRAFV600-mutant melanoma (coBRIM): updated efficacy results from a randomised, double-blind, phase 3 trial
PA Ascierto, GA McArthur, B Dréno, V Atkinson, G Liszkay, ...
The lancet oncology 17 (9), 1248-1260, 2016
6752016
A microenvironment-induced myeloproliferative syndrome caused by retinoic acid receptor γ deficiency
CR Walkley, GH Olsen, S Dworkin, SA Fabb, J Swann, GA McArthur, ...
Cell 129 (6), 1097-1110, 2007
5102007
Recombinant NY-ESO-1 protein with ISCOMATRIX adjuvant induces broad integrated antibody and CD4+ and CD8+ T cell responses in humans
ID Davis, W Chen, H Jackson, P Parente, M Shackleton, W Hopkins, ...
Proceedings of the National Academy of Sciences 101 (29), 10697-10702, 2004
4982004
The system can't perform the operation now. Try again later.
Articles 1–20